Pharming (PHAR) Short term Debt (2019 - 2026)
Pharming's (PHAR) quarterly Short term Debt came in at $92.4 million in Q2 2026, up 1.24% YoY from $91.3 million in Q2 2025, and down 1.06% on a QoQ basis from $93.4 million in Q1 2026.
Pharming (PHAR) Short term Debt (2019 - 2026) Analysis & Trends
Pharming (PHAR) has 8 years of Short term Debt data on file, last reported at $92.4 million in Q2 2026.
- Quarterly Short term Debt rose 1.24% year-over-year to $92.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $92.4 million (up 1.24% YoY) and the FY2025 annual result came in at $92.7 million, up 168.72% from the prior year.
- Short term Debt declined to $92.4 million in Q2 2026, from $93.4 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $135.6 million in Q1 2022 to a low of -$134.9 million in Q3 2024.
- A 5-year average of $72.4 million and a median of $92.6 million in 2025 frame the typical range for Short term Debt.
- Annual changes were most pronounced in 2023 — Short term Debt jumped 108006.33% — and 2024, when it tumbled 204.01%.
- Tracing PHAR's Short term Debt over 5 years: stood at $1.8 million in 2022, then rose by 3.17% to $1.8 million in 2023, then soared by 132.73% to $4.2 million in 2024, then jumped by 2084.19% to $92.7 million in 2025, then fell by 0.34% to $92.4 million in 2026.
- The last three Short term Debt figures came in at $92.4 million (Q2 2026), $93.4 million (Q1 2026), and $92.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 92.40 Mn |
| Mar 31, 2026 | 93.39 Mn |
| Dec 31, 2025 | 92.72 Mn |
| Sep 30, 2025 | 93.14 Mn |
| Jun 30, 2025 | 91.27 Mn |
| Mar 31, 2025 | 83.85 Mn |
| Dec 31, 2024 | 4.25 Mn |
| Sep 30, 2024 | -134.93 Mn |
| Jun 30, 2024 | 87.32 Mn |
| Mar 31, 2024 | 134.89 Mn |
| Dec 31, 2023 | 1.82 Mn |
| Sep 30, 2023 | 129.73 Mn |
| Jun 30, 2023 | 134.18 Mn |
| Mar 31, 2023 | 133.58 Mn |
| Dec 31, 2022 | 1.77 Mn |
| Sep 30, 2022 | 120,005.00 |
| Jun 30, 2022 | 128.24 Mn |
| Mar 31, 2022 | 135.56 Mn |
| Dec 31, 2021 | 140,303.46 |
| Sep 30, 2021 | 140.96 Mn |